Design of a water-soluble CD20 antigen with computational epitope scaffolding.

Protein Sci

Department of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

Published: August 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The poor solubility of integral membrane proteins in water frequently hinders studies with these proteins, presenting challenges for structure determination and binding screens. For instance, the transmembrane protein CD20, which is an important target for treating B-cell malignancies, is not soluble in water and cannot be easily screened against potential protein binders with techniques like phage display or yeast display. Here, we use de novo protein design to create a water-soluble mimic of the core epitope of the CD20 dimer ("soluble CD20"). Soluble CD20 replaces the central transmembrane helix of CD20 with a water-soluble helix that dimerizes to form a coiled coil that structurally matches the dimer interface of native CD20 and presents the second extracellular loop (ECL2) of CD20 in a binding competent conformation. Unlike peptides derived from CD20, soluble CD20 binds tightly to monoclonal antibodies that recognize quaternary epitopes on the extracellular face of CD20. We demonstrate that soluble CD20 is easy to produce, remains folded above 60°C, and is compatible with binder screening via yeast display. Our results highlight the ability of computational protein design to scaffold conformational epitopes from membrane proteins for use in binding and protein engineering studies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12267654PMC
http://dx.doi.org/10.1002/pro.70184DOI Listing

Publication Analysis

Top Keywords

soluble cd20
12
cd20
11
membrane proteins
8
yeast display
8
protein design
8
protein
5
design water-soluble
4
water-soluble cd20
4
cd20 antigen
4
antigen computational
4

Similar Publications

[Experiences after CD19-CAR T-cell therapy in non-SLE connective tissue diseases].

Z Rheumatol

September 2025

Medizinische Klinik V für Hämatologie, Onkologie und Rheumatologie, Sektion Rheumatologie, Universitätsklinikum Heidelberg, INF 410, 69120, Heidelberg, Deutschland.

The treatment of fibrosing autoimmune diseases has so far shown no significant progress with respect to fibrosis. The reason for this is unclear. As in vitro and in vivo data have shown that B‑lymphocytes are not only responsible for autoantibody production but also play an important role in the activation of fibroblasts in an inflammatory event, depletion of B cells is meaningful in these fibrosing autoimmune diseases.

View Article and Find Full Text PDF

Design of a water-soluble CD20 antigen with computational epitope scaffolding.

Protein Sci

August 2025

Department of Biochemistry and Biophysics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

The poor solubility of integral membrane proteins in water frequently hinders studies with these proteins, presenting challenges for structure determination and binding screens. For instance, the transmembrane protein CD20, which is an important target for treating B-cell malignancies, is not soluble in water and cannot be easily screened against potential protein binders with techniques like phage display or yeast display. Here, we use de novo protein design to create a water-soluble mimic of the core epitope of the CD20 dimer ("soluble CD20").

View Article and Find Full Text PDF

The recent surge in T-cell-engaging and chimeric antigen receptor (CAR) T-cell therapies is changing the landscape of cancer therapy. Cytokine release syndrome (CRS) is a systemic inflammatory response syndrome that is a well-known complication of these therapies, of which interleukin-6 (IL-6) is a key mediator. Tocilizumab, an IL-6 receptor (IL-6R) antagonist, is approved for the management of CAR T-cell therapy-induced CRS in adults and in pediatric patients aged ≥ 2 years old.

View Article and Find Full Text PDF

: We describe a case of intravascular large B-cell lymphoma (IVLBCL) presenting with recurrent cerebral infarctions and review similar reported cases. Our aim is to explore potential early diagnostic markers and discuss their prognostic implications. : A 79-year-old man with a history of hypertension, hyperuricemia, and postoperative bladder cancer presented with five to six cerebral infarctions over an 11-month period, despite successive changes in antiplatelet and anticoagulant medications.

View Article and Find Full Text PDF

Introduction: Waldenström macroglobulinemia is a low-grade B-cell lymphoma characterized by lymphoplasmacytic lymphoma infiltration of the bone marrow and immunoglobulin M (IgM) protein.

Case Presentation: An 80s-year-old male presented to our hospital with chief complaints of weight loss and general fatigue. Computed tomography (CT) showed homogeneous tumor around the kidney with elevated soluble Interleukin-2 receptor, serum IgM, and β2-microglobulin levels.

View Article and Find Full Text PDF